ARS Pharmaceuticals cut to outperform from strong buy; target price cut to $17 from $28
SPRY•Raymond James cut its rating on ARS Pharmaceuticals to outperform from strong buy and lowered its target price to $17 from $28.
Related News
Marcus & Millichap Q3 revenue rises on higher brokerage sales volume
MMI•
GE Vernova wins PowerGrid order for 6 GW power transmission project in India
GEV•
ICU Medical presents at Jefferies Global Healthcare Conference
ICUI•
Applied Optoelectronics target cut by B. Riley to $45 from $92
AAOI•
Susquehanna cuts MACOM Technology Solutions target price to $220 from $300
MTSI•